Biohaven Announces Progress Across Its Graves' Disease Program, Including Active Enrollment In Pivotal Phase 3 Trial Of BHV-1300 And Three Scientific Presentations At The American Thyroid Association Meeting; Phase 3 Trial Of BHV-1300 In Graves' Disease Is Enrolling At 55+ Active Sites In U.S. And Canada, With More Opening In UK, Japan, Australia And EU
Biohaven presents three posters at ATA, highlighting the patient experience, autoimmune biology of disease, and MoDE and TRAP platform, reflecting a research program built around a condition that remains strikingly
Biohaven is testing a new medicine for Graves' Disease in a big trial. This shows the company is moving forward with research and finding patients to test it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.